Compare Amgen, Inc. (AMGN) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Prudential Financial Inc — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Prudential Financial Inc trades at $116.38 (market cap $40.07B). The key difference: Amgen, Inc. is far larger — about 4.9× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.85%). Which is the better fit depends on your goals.
| AMGN | PRU | |
|---|---|---|
Market Cap | $196.12B | $40.07B |
Sector | Health | Financials |
52-Week High | $388.16 | $118.72 |
52-Week Low | $271.18 | $92.00 |
Enterprise Value | $241.41B | $67.13B |
Dividend Yield | 2.77% | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PRU trades at $115.37, up 0.32% on the day, with a bullish technical signal and strong support at $113. The stock shows solid fundamentals with a P/E of 11.88 and net income margin of 5.5%, while recent earnings beats in Q1 2026 and dividend announcements highlight financial stability. News coverage emphasizes expansion in retirement products and international markets.
Outlook remains positive given valuation discounts and earnings momentum, though risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, but the stock's current technical strength and fundamental metrics support a steady growth trajectory for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
